DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PFIZER LTD (PFIZER) share price today?

PFIZER LTD (PFIZER) is trading at ₹4,566.9 on the NSE, down 2.79% on the day. Source: DocStoX.

What is the PE ratio of PFIZER LTD?

PFIZER LTD has a price-to-earnings (PE) ratio of 27.2 in the Healthcare sector.

What is the market capitalisation of PFIZER LTD?

PFIZER LTD has a market capitalisation of approximately ₹20,903 crore.

PFIZER LTD

PFIZER·NSE·Healthcare

₹4,566.90▼ -130.90 (-2.79%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

NIFTY 500NIFTY SMALLCAP 250

Day₹4502.60

₹4609.00

52W₹4360

₹587414%

Open

₹4600.00

High

₹4609.00

Low

₹4502.60

Prev Close

₹4697.80

Volume

32.7K

VWAP

₹4572.40

Snapshot

Key fundamentals

Market Cap

₹20,903 Cr

P/E Ratio

27.22Fair

P/B Ratio

5.01

EPS

₹167.79

Book Value

₹918.71

ROE

18.20%Strong

ROCE

21.00%Efficient

Dividend Yield

1.63%

Debt / Equity

0.02Low

Face Value

₹10.00

52W High

₹5873.50

52W Low

₹4360.10

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹1,326

▼ 71.0%downside

Trading at ₹4,567 — 71% above our estimate

BearFair valueBull

₹1,127₹1,326₹1,862

/100

Business quality — Solid

Growth 0Profitability 83Efficiency 41Valuation 78

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 21%)
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

18% ROE fading to 12% over ~10 yrs, on ₹919 book

₹1,177

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹1,862

Analyst target

No analyst coverage

—

Blended fair value₹1,326

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 21%)
Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

27.2Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

18.2%Strong

Above 15% is considered healthy for Indian equities

ROCE

21.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.02Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹20,903 Cr

P/B

5.01

EPS

₹167.79

Div Yield

1.63%

What changed

Recent changes

Foreign investors+0.1% stake last quarter
Domestic institutions-0.2% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 27.2×

Growth

Slow

+1% rev CAGR

Profitability

Excellent

18.2% ROE

Financial health

Rock solid

D/E 0.02

Momentum

N/A

No technicals

Today

Trading activity

Delivery %42.1%

Turnover₹1496.59L Cr

Trades8,205

VWAP₹4572.40

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+1.3%

+2.4%

10Y

+2.3%

Profit

+5.0%

+7.7%

10Y

+9.0%

EPS

—

10Y

—

Profile

Pros

Company has reduced debt.
Company is almost debt free.
Company has been maintaining a healthy dividend payout of 58.3%

Watch-outs

Cons

The company has delivered a poor sales growth of 2.39% over past five years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.10 pts; domestic institutions reduced 0.16 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

64%

Promoter

Promoters

63.9%0.00

Public

11.9%-0.06

FII / FPI

2.8%+0.10

DII

16.9%-0.16

Others

4.5%

Total shareholders

99,545-1,388 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter63.92%

FII2.81%

DII16.89%

Public11.87%

Others4.51%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

PFIZER LTD valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

PFIZER LTD peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD CIPLA LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED

Compare PFIZER LTD with peers

PFIZER LTD vs SUN PHARMACEUTICAL IND L PFIZER LTD vs DIVI S LABORATORIES LTD PFIZER LTD vs TORRENT PHARMACEUTICALS L PFIZER LTD vs APOLLO HOSPITALS ENTER. L PFIZER LTD vs ZYDUS LIFESCIENCES LTD PFIZER LTD vs CIPLA LTD

PFIZER LTD

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

PFIZER LTD valuation & research

PFIZER LTD peers in Healthcare

Compare PFIZER LTD with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions